Display options
Cite
Vaes RDW, Reynders K, Sprooten J, et al. Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246259.
Vaes, R. D. W., Reynders, K., Sprooten, J., Nevola, K. T., Rouschop, K. M. A., Vooijs, M., Garg, A. D., Lambrecht, M., Hendriks, L. E. L., Rucevic, M., & De Ruysscher, D. (2021). Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study. Cancers, 13(24), . https://doi.org/10.3390/cancers13246259
Vaes, Rianne D W, et al. "Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246259
Vaes RDW, Reynders K, Sprooten J, Nevola KT, Rouschop KMA, Vooijs M, Garg AD, Lambrecht M, Hendriks LEL, Rucevic M, De Ruysscher D. Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study. Cancers (Basel). 2021 Dec 13;13(24). doi: 10.3390/cancers13246259. PMID: 34944879.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Dec 13;13(24). doi: 10.3390/cancers13246259.

Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study.

Cancers

Rianne D W Vaes, Kobe Reynders, Jenny Sprooten, Kathleen T Nevola, Kasper M A Rouschop, Marc Vooijs, Abhishek D Garg, Maarten Lambrecht, Lizza E L Hendriks, Marijana Rucevic, Dirk De Ruysscher

Affiliations

  1. Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.
  2. Cell Stress & Immunity (CSI) Lab, Department for Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.
  3. OLINK Proteomics Inc., Waltham, MA 02453, USA.
  4. Department of Radiotherapy, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.
  5. Department of Radiotherapy-Oncology, Leuven Kanker Instituut, Universitair Ziekenhuis (UZ) Gasthuisberg, 3000 Leuven, Belgium.
  6. Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

PMID: 34944879 DOI: 10.3390/cancers13246259

Abstract

Radiotherapy (RT) and chemotherapy can induce immune responses, but not much is known regarding treatment-induced immune changes in patients. This exploratory study aimed to identify potential prognostic and predictive immune-related proteins associated with progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC). In this prospective study, patients with stage I NSCLC treated with stereotactic body radiation therapy (

Keywords: biomarkers; chemoradiation; immunogenic cell death; non-small cell lung cancer; predictive; prognostic; stereotactic body radiotherapy

References

  1. J Immunother Cancer. 2020 Mar;8(1): - PubMed
  2. Lung Cancer. 2021 May;155:103-113 - PubMed
  3. Cancer Res. 2007 Apr 1;67(7):3396-405 - PubMed
  4. Oncoimmunology. 2018 Nov 2;8(1):e1523097 - PubMed
  5. Cancer Res. 2007 Jun 15;67(12):5940-8 - PubMed
  6. Nat Med. 2014 Nov;20(11):1301-9 - PubMed
  7. Front Immunol. 2020 Oct 14;11:580237 - PubMed
  8. Int J Oncol. 2012 Feb;40(2):560-6 - PubMed
  9. N Engl J Med. 2017 Nov 16;377(20):1919-1929 - PubMed
  10. Nat Med. 2007 Jan;13(1):54-61 - PubMed
  11. Ann Oncol. 2021 Jul;32(7):881-895 - PubMed
  12. Science. 2015 Nov 20;350(6263):972-8 - PubMed
  13. Nat Immunol. 2009 Jan;10(1):29-37 - PubMed
  14. J Leukoc Biol. 2005 Nov;78(5):1043-51 - PubMed
  15. J Hematol Oncol. 2016 Nov 3;9(1):116 - PubMed
  16. Cancer Immunol Res. 2017 Oct;5(10):898-907 - PubMed
  17. Immunol Lett. 2004 Jun 15;94(1-2):141-51 - PubMed
  18. J Clin Invest. 2007 May;117(5):1155-66 - PubMed
  19. Science. 2011 Dec 16;334(6062):1573-7 - PubMed
  20. Cancer Gene Ther. 2021 Feb 18;: - PubMed
  21. Lancet. 2016 Apr 9;387(10027):1540-1550 - PubMed
  22. Ann Oncol. 2020 Jun;31(6):798-806 - PubMed
  23. Cell Death Dis. 2020 Nov 26;11(11):1013 - PubMed
  24. Nat Med. 2009 Oct;15(10):1170-8 - PubMed
  25. PLoS One. 2014 May 05;9(5):e93523 - PubMed
  26. EMBO J. 2012 Mar 7;31(5):1062-79 - PubMed
  27. J Thorac Oncol. 2020 Feb;15(2):288-293 - PubMed
  28. Transl Lung Cancer Res. 2021 Jun;10(6):2475-2486 - PubMed
  29. PLoS One. 2015 Oct 06;10(10):e0139598 - PubMed
  30. J Exp Med. 2021 Sep 6;218(9): - PubMed
  31. Nat Rev Immunol. 2017 Feb;17(2):97-111 - PubMed
  32. Int J Mol Sci. 2018 Dec 09;19(12): - PubMed
  33. Front Immunol. 2018 Nov 28;9:2809 - PubMed
  34. Chest. 2000 Feb;117(2):365-73 - PubMed
  35. J Immunother Cancer. 2021 Nov;9(11): - PubMed
  36. J Clin Invest. 2011 Jun;121(6):2350-60 - PubMed
  37. Front Immunol. 2021 Mar 08;12:626776 - PubMed
  38. Cell Res. 2010 Jan;20(1):34-50 - PubMed
  39. Cell Mol Immunol. 2019 Jan;16(1):6-18 - PubMed
  40. Immunogenetics. 1992;35(6):378-84 - PubMed
  41. Nat Commun. 2017 Jun 09;8:15618 - PubMed
  42. Cell Death Differ. 2017 May;24(5):832-843 - PubMed
  43. Int J Radiat Biol. 2009 Dec;85(12):1126-36 - PubMed
  44. Annu Rev Immunol. 2011;29:235-71 - PubMed
  45. N Engl J Med. 2018 Dec 13;379(24):2342-2350 - PubMed
  46. Front Oncol. 2020 Oct 13;10:584261 - PubMed
  47. Immunol Rev. 2007 Dec;220:22-34 - PubMed
  48. Chin J Cancer Res. 2017 Oct;29(5):463-470 - PubMed
  49. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237 - PubMed
  50. Nat Med. 2007 Sep;13(9):1050-9 - PubMed
  51. J Thorac Oncol. 2021 Apr;16(4):653-664 - PubMed
  52. Tumour Biol. 2014 May;35(5):4191-8 - PubMed
  53. J Thorac Oncol. 2020 Oct;15(10):1657-1669 - PubMed
  54. Cancer Res. 2011 Jul 15;71(14):4821-33 - PubMed
  55. J Thorac Oncol. 2021 Nov;16(11):1909-1924 - PubMed
  56. Nat Immunol. 2012 Sep;13(9):832-42 - PubMed
  57. Br J Cancer. 2015 Jul 14;113(2):327-35 - PubMed
  58. Cell Death Differ. 2008 Sep;15(9):1499-509 - PubMed
  59. J Immunol. 2005 Jun 1;174(11):6791-802 - PubMed
  60. J Thorac Oncol. 2021 Nov;16(11):1872-1882 - PubMed
  61. Cold Spring Harb Perspect Biol. 2019 Mar 1;11(3): - PubMed
  62. J Clin Invest. 2012 Mar;122(3):787-95 - PubMed
  63. Eur Respir J. 2020 Feb 6;55(2): - PubMed
  64. J Thorac Oncol. 2021 May;16(5):860-867 - PubMed
  65. PLoS One. 2011 Mar 31;6(3):e18426 - PubMed
  66. Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44 - PubMed
  67. Front Immunol. 2018 May 04;9:847 - PubMed
  68. Cell Death Differ. 2018 Mar;25(3):486-541 - PubMed
  69. BMC Cancer. 2020 Jun 15;20(1):557 - PubMed
  70. J Thorac Oncol. 2020 Aug;15(8):1351-1360 - PubMed
  71. Oncotarget. 2015 Sep 29;6(29):26841-60 - PubMed
  72. Ann Transl Med. 2019 Oct;7(20):542 - PubMed
  73. J Clin Oncol. 2021 Jul 20;39(21):2339-2349 - PubMed
  74. Lancet Oncol. 2015 Oct;16(13):e498-509 - PubMed
  75. Cells. 2021 Apr 17;10(4): - PubMed
  76. Oncotarget. 2014 Jan 30;5(2):403-16 - PubMed
  77. J Thorac Oncol. 2021 Oct;16(10):1718-1732 - PubMed

Publication Types